CABG Delivers Survival Benefit in Ischemic Cardiomyopathy

• Autores: Anita Slomski
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 20, 2016, pág. 2159
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Among patients who had coronary artery bypass graft (CABG) procedures in addition to medical therapy for coronary artery disease, heart failure, and severe left ventricular systolic dysfunction, the rate of death from any cause was 16% lower over a decade compared with patients treated with medical therapy alone (Velazquez EJ et al. N Engl J Med. 2016;374:1511-1520). The significant survival benefit was evident only in the long-term follow-up of the previously published Surgical Treatment for Ischemic Heart Failure (STICH) trial (Velazquez EJ et al. N Engl J Med. 2011;364:1607-1616); at approximately 5 years, there was no significant difference in all-cause mortality between those who had surgical revascularization vs those who had only medical therapy.